CASI Pharmaceuticals, Inc. (CASIF)
About CASI Pharmaceuticals, Inc.
CASI PHARMACEUTICALS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $20.7M
- Net income
- -$48.1M
- Total assets
- $25.6M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
CASI Pharmaceuticals, Inc. (CASIF) Stock Price
- Reported a net loss of $48.1M in FY2025.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CASI Pharmaceuticals, Inc..
Write a review
CASI Pharmaceuticals, Inc.: frequently asked questions
Is CASI Pharmaceuticals, Inc. an American company?
CASI Pharmaceuticals, Inc. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is CASI Pharmaceuticals, Inc. publicly traded?
Yes — CASI Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol CASIF on the OTC.
What does CASI Pharmaceuticals, Inc. do?
CASI Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
